Expand BFRI Menu
BFRI MENU

BFRI Latest Press Releases

-- January 8, 2026 --

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones Globe Newswire 8:45 AM

-- December 18, 2025 --

Biofrontera Inc. Completes Transfer of Ameluz and RhodoLED FDA approval and Associated Intellectual Property Portfolio Globe Newswire 8:45 AM

-- December 4, 2025 --

Last Patient Completes Biofrontera's Phase 1 Pharmacokinetics Study of Ameluz for Treatment of Actinic Keratoses on the Trunk and Extremities Globe Newswire 9:00 AM

-- December 2, 2025 --

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz-PDT Globe Newswire 8:45 AM

-- November 13, 2025 --

Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update Globe Newswire 8:15 AM

-- November 7, 2025 --

Biofrontera Inc. announces sale of license to Xepi Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M Globe Newswire 8:00 AM

-- November 6, 2025 --

Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025 Globe Newswire 4:01 PM

-- October 23, 2025 --

Biofrontera Inc. Closes Purchase of All Ameluz and RhodoLED US Assets from Biofrontera AG Globe Newswire 8:51 AM

-- September 26, 2025 --

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 Globe Newswire 9:15 AM

-- September 23, 2025 --

Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program Globe Newswire 9:20 AM

-- September 16, 2025 --

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk Globe Newswire 10:30 AM

-- August 25, 2025 --

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris Globe Newswire 8:25 AM

-- August 13, 2025 --

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update Globe Newswire 5:20 PM

-- August 11, 2025 --

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer Globe Newswire 4:25 PM
Market Data Delayed 15 Minutes